
Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.

Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.

The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.

In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated questionnaire.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

Infectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer UTI agents.

New ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.

An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.

Cardiologists and pharmacy leaders explained how team-based clinics and standardized paperwork are speeding obstructive HCM treatment.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

San Francisco experts say payer step edits and weak biologic follow-up slow atopic dermatitis care and point to pharmacy teams and dashboards.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.

IL-23 inhibitors linked to lower psoriatic arthritis risk than JAK inhibitors, and IL-17 inhibitors showed higher risk.

FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

In the phase 3 ECLIPSE 1 trial, 44% on elebsiran plus tobevibart met the primary end point, with no treatment stops due to serious adverse events.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

A TriNetX retrospective cohort found adults with alopecia areata—especially women—face a nearly doubled glaucoma risk, with implications for ophthalmology and comorbidities.

β3 agonists were not linked to lower dementia incidence vs anticholinergics among 830,393 adults treated for overactive bladder, a cohort study found.

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.

In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.

From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.

New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.

A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.

Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

One-year open-label MINT data show sustained MG-ADL and QMG score gains with inebilizumab, including in patients who switched from placebo.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.